Melanotan I (Afamelanotide): Evidence, Mechanism & Legal Status

Melanotan I (afamelanotide; CUV1647; CAS 75921-69-6) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that drives photoprotective pigmentation. It is best known online as a self-injected tanning peptide, yet it is also the only melanocortin agonist with FDA approval for any indication.17 Those two identities — a legitimate orphan drug and an unregulated 'research chemical' — are the heart of this monograph, and they must not be conflated.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. The FDA-approved SCENESSE implant is administered only by trained clinicians; the injected gray-market 'melanotan-1' is an unapproved product of unknown purity. Doses and routes are reported strictly as they appear in the FDA label and published trials, for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Melanotan I and how does it work?

Afamelanotide is a synthetic linear tridecapeptide analogue of human alpha-MSH, structurally [Nle4-D-Phe7]-alpha-MSH: methionine at position 4 is replaced by norleucine and L-phenylalanine at position 7 by D-phenylalanine.131 Those two substitutions confer resistance to proteolytic degradation and substantially greater potency and duration of action than native alpha-MSH.10

Like all melanocortins it can engage the MC1-MC5 receptor family, but at therapeutic exposure afamelanotide is functionally MC1R-predominant, with minimal MC3R/MC4R/MC5R activity. This distinguishes it from the non-selective tanning peptide Melanotan II, which activates MC4R and produces erections, nausea and autonomic effects.211 The mechanism is well characterized: afamelanotide binds MC1R on epidermal melanocytes, activates adenylyl cyclase, raises intracellular cAMP, and engages the MITF transcription pathway, which upregulates tyrosinase — the rate-limiting enzyme of melanogenesis — shifting synthesis toward eumelanin, the photoprotective brown-black pigment.121 The increased epidermal eumelanin absorbs, scatters and quenches the visible and UV light that, in EPP, photo-activates accumulated protoporphyrin IX and triggers phototoxic pain.1 MC1R signaling also has melanin-independent antioxidant and anti-inflammatory effects and is reported to stimulate DNA repair.2 A newer mechanistic finding is that UV and alpha-MSH drive MC1R into primary cilia via the BBSome, sustaining cAMP signaling and Sox9-mediated upregulation of melanogenesis genes.12

On pharmacokinetics: the approved product is a controlled-release bioresorbable subcutaneous implant; pigmentation appears within roughly two days and the implant releases drug over about two months, which supports the every-60-day regimen.511 Free peptide is rapidly hydrolyzed to component amino acids, and afamelanotide is not a cytochrome P450 substrate; the FDA label does not state a discrete plasma half-life, so secondary 'half-life' figures should be treated as approximate.110

What is the evidence by indication?

The evidence is sharply tiered: robust for EPP, suggestive for vitiligo, and essentially absent for the tanning use that drives the online market.

The pivotal EPP evidence is two multicenter, randomized, double-blind, placebo-controlled phase 3 trials of the 16 mg implant versus placebo, pooled in Langendonk et al., NEJM 2015 (total enrolled n=168).2 In the US trial (6 months, 3 implants), median pain-free direct-sunlight time was 69.4 hours on afamelanotide versus 40.8 hours on placebo (P=0.04); in the EU trial (9 months, 5 implants), median pain-free time was 6.0 hours versus 0.8 hours (P=0.005), with fewer phototoxic reactions (77 vs 146; P=0.04) and significantly improved quality of life.2 This underpinned EMA approval in 2014-2015 and FDA approval in 2019, and it is reinforced by large post-authorization cohorts: a German PASS study of 200 EPP patients reported EPP-QoL gains averaging roughly 100% with 91% treatment continuation and a safety profile consistent with the trials.9 The pivotal phase 3 results are catalogued on PubMed at pubmed.ncbi.nlm.nih.gov for the vitiligo program and across the NEJM record for EPP, and readers can verify the prescribing details directly in the FDA label.4

For vitiligo, a randomized multicenter trial (Lim et al., JAMA Dermatology 2015) added monthly 16 mg afamelanotide to narrowband UV-B and produced greater repigmentation (48.6% vs 33.3%) and faster onset, with benefit concentrated in darker skin types — but the trials are small and afamelanotide is not FDA-approved for vitiligo as of 2026.315 For cosmetic tanning, despite being the very molecule sold online for that purpose, there are no phase 3 efficacy or safety trials, and no regulator approves it for tanning.2021

What doses appear in the literature?

Reported strictly as information, not a protocol. The approved EPP regimen is one 16 mg afamelanotide bioresorbable implant — a sterile white-to-off-white rod about 1.7 cm long — inserted subcutaneously above the anterior supra-iliac crest every 2 months by a healthcare professional trained in the implantation procedure.57 In the pivotal trials, the US phase 3 used 3 implants over 6 months and the EU phase 3 used 5 implants over 9 months; the vitiligo RCT used monthly 16 mg implants for 4 months alongside NB-UVB.23 The implant requires no reconstitution — it is a solid, pre-formed bioresorbable rod, not a reconstituted injectable. The gray-market 'melanotan-1' tanning product is, by contrast, a lyophilized powder reconstituted and self-injected outside the approved route, with no quality assurance and no validated tanning dose.20

How safe is Melanotan I?

For the approved implant, the common adverse reactions on the FDA label (incidence over 2%) include implant-site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus and skin irritation; in pooled trials, implant-site reactions ran about 21% versus 10% on placebo, and events were predominantly mild-to-moderate and transient.51 Because afamelanotide darkens pre-existing nevi and freckles, the label requires a full-body skin examination twice yearly to monitor for new or changing pigmented lesions.5 Reassuringly, in the German PASS cohort, 30.5% reported pigmentary expressions and the biopsies performed were all histologically benign, with no drug-attributed malignancies; the trials reported one melanoma — in the placebo arm.92

The important distinction is that the alarming melanoma and eruptive-nevi case reports in the lay and case literature predominantly involve the non-selective gray-market Melanotan II, not regulated afamelanotide — but the theoretical concern of a melanocyte-proliferative stimulus is exactly why the label mandates dermatologic surveillance for any melanocortin tanning agent.181 Rare postmarketing hypersensitivity reactions including anaphylaxis have been reported; LiverTox rates hepatotoxicity likelihood as low.51 The only contraindication is a history of severe hypersensitivity to afamelanotide or its excipients, and there are no human pregnancy data.5 Crucially, none of the favorable safety data from the regulated implant transfer to the gray-market injected product, which carries contamination, sterility and dosing-accuracy hazards absent from the approved route.1920

What is the FDA and WADA status in 2026?

The FDA approved afamelanotide on October 8, 2019 as SCENESSE — a first-in-class MC1R agonist implant — to increase pain-free light exposure in adults with EPP, with Orphan Drug and Priority Review designations; the prescribing information was most recently revised in August 2024.75 The EMA approved it for EPP in 2014-2015 (with an earlier Italian AIFA approval in 2010).14 There is no approved indication for cosmetic tanning or vitiligo, and the injectable 'melanotan-1' sold online for tanning is an unapproved new drug — the same molecule but not the FDA-approved product, typically labeled 'not for human use,' against which the FDA has historically pursued enforcement.2023 Melanotan peptides are not scheduled controlled substances; the legal issue is unapproved-drug marketing, not the Controlled Substances Act.22

For athletes the picture is unambiguous: non-approved peptide-hormone analogues fall under WADA Section S2 (peptide hormones, growth factors, related substances and mimetics), prohibited in and out of competition, and afamelanotide's narrow EPP approval does not create a doping exemption.1617 Any WADA-tested athlete should treat melanotan as prohibited regardless of cosmetic intent.

Bottom line. Afamelanotide is the rare gray-market-famous peptide that genuinely earned its approval — for one narrow, well-studied indication. In adults with EPP, the 16 mg every-2-month implant meaningfully increases pain-free sunlight tolerance on Grade-A RCT evidence with a benign monitored safety profile. Vitiligo (Grade B) is promising but unapproved. Cosmetic tanning — the use that drives the online market — has no efficacy or safety RCTs, no approval, and is sourced from unregulated products of unknown purity. The clear line to hold: the approved EPP implant is legitimate, clinician-administered medicine; the injected tanning peptide is an unapproved, unstudied, unregulated product. Regulatory facts are current as of June 2026 and should be re-verified for any later label or list changes.